Enable JavaScript to ensure website accessibility
Precipio, Inc. Announces Pricing of $2 Million Registered Direct Offering and Concurrent Private Placement

NEW HAVEN, CT, (June 8th, 2023) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), today announced it [...]

Projected cash burn reduced by $1.5 million annually from Three Operational Efficiency Projects

Independent of revenue growth, these Projects expected to decrease cash burn by 25% in Q3 [...]

Precipio Shares Growth Catalysts For HemeScreen

Q1 Results and catalysts show promising growth trajectory NEW HAVEN, CT, (May 17th, 2023) – Specialty [...]

Precipio Announces Q1-2023 Shareholder Update Call

Conference Call to be held on May 17, 2023 at 5:00 PM EST NEW HAVEN, [...]

Precipio Adds Substantial Pathology Customer to its Diagnostic Services Division

Customer’s pathology services annual revenues expected to exceed $1.5M NEW HAVEN, CT, Globenewswire – (May [...]

Precipio Signs Another HemeScreen™ Customer

Customer’s revenues expected at $750K at full capacity NEW HAVEN, CT, Globenewswire – (May 4th, [...]

Precipio Granted 180-day Extension From NASDAQ To Regain Compliance

Extension will enable the Company to execute on its growth and advance toward breakeven NEW [...]

Precipio Unaudited Q1-2023 Product Revenues Exceed The Two Prior Quarters (Q3+Q4 of 2022) Combined

Q1-2023 product revenues approximately $0.76M exceeded the $0.66M combined revenue of Q3+Q4 2022 NEW HAVEN, [...]

Precipio Announces 2022 Fourth Quarter and Year-End Shareholder Update Call

Conference Call to be held on Monday, April 3rd, 2023 at 5:00 PM EST NEW [...]

Precipio Ships First IV-Cell® Order to Major US Healthcare System

Products Division revenues begin to diversify beyond HemeScreen® NEW HAVEN, CT, Globenewswire – (March 21st, [...]